TY - JOUR T1 - Ramipril improves walking times and quality of life in patients with stable intermittent claudication JF - Evidence Based Medicine JO - Evid Based Med SP - 16 LP - 16 DO - 10.1136/eb-2013-101301 VL - 19 IS - 1 AU - Julie Brittenden Y1 - 2014/02/01 UR - http://ebm.bmj.com/content/19/1/16.abstract N2 - Commentary on: Ahimastos AA, Walker PJ, Askew C, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 2013;309:453–60.OpenUrlCrossRefPubMedWeb of Science Intermittent claudication (IC) is a common condition that may be associated with significant disability and reduction in quality of life. Pharmacological options for the treatment of the symptoms of this condition are very limited. Naftidrofuryl oxalate is recommended in the National Institute for Health and Care Excellence (NICE) guidelines,1 and while this has been shown to improve pain-free and maximal walking distances, its effect, if any, on quality of life is unknown. ACE inhibitors (ACEI) are believed to have the potential to improve blood flow, endothelial function, and alter muscle metabolism and structure. Previous small studies involving ACEI have shown … ER -